Carlo Russo has joined a growing list of ex-GlaxoSmithKline staffers moving into biotech after working on and helping launch the Big Pharma’s rare disease drug…

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO.

Johns Hopkins researchers have landed on a synthetic peptide with effects lasting twice as long as the standard drug's, representing a potential…

Biogen is joining forces with Siemens Healthineers to develop MRI applications to quantify “key markers” indicating multiple sclerosis activity and progression.

Takeda, pushing on with its U.S. biotech R&D odyssey, has signed a research deal and collab with New York’s private biotech Ovid that will see the small…

A phase 2 trial of Neurocrine’s Ingrezza in Tourette syndrome has missed its primary endpoint.

When there are financial ties between researchers working on a clinical study and the drug industry, the data from these tests are more likely to be positive,…

Women’s health biotech ObsEva has set the terms for an IPO that could net it in the region of $87 million.

President-elect Trump’s pick for HHS secretary bought shares in Zimmer Biomet, then introduced a bill that would have directly helped the company.